Ryan Fuhrmann

InvestorPlace Contributor

Ryan C. Fuhrmann, CFA, has a background in portfolio management, overseeing assets for high-net-worth individuals and covering a broad array of industries from a generalist perspective. An active student of investing, he is also committed to communicating his ideas as an investment writer and learning from the financial community. His Twitter handle is @rationalanalyst.

Recent Articles

3 Beaten-Down Generic Drugmakers to Buy

By Ryan Fuhrmann, InvestorPlace Contributor Dec 5, 2016

Generic drugmakers Mylan (MYL), Teva (TEVA) and Novartis (NOV) took a hit from DOJ subpoenas on speculation of price-fixing in the industry.

Facebook Inc (FB) Is a Better Bet Than Alphabet Inc (GOOGL)

By Ryan Fuhrmann, InvestorPlace Contributor Dec 1, 2016

Facebook (FB) might look expensive in a bubble, but given the ludicrous growth expectations for this blue chip, Facebook stock is a value.

3 Beaten-Down Biotech Stocks to Buy for Huge Gains

By Ryan Fuhrmann, InvestorPlace Contributor Nov 17, 2016

The following are three Biotech stocks to buy because of their long-term potential, which surpasses the recent onslaught of negative press and concern over higher drug prices.

3 Beaten-Down Healthcare Stocks to Buy

By Ryan Fuhrmann, InvestorPlace Contributor Nov 2, 2016

Allergan (AGN), Zimmer Biomet (ZBH) and McKesson (MCK) are three bona fide leaders in their respective healthcare industries.

3 Blue-Chip Stocks With Hidden Benefits

By Ryan Fuhrmann, InvestorPlace Contributor Oct 26, 2016

Returns come in many forms. These three blue-chip stocks offer some of the best benefits to investors that purchase their shares.